Live

FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan FDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical Needs Endpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical win BioPharma DiveBiotech layoffs are easing, but is the worst over?FierceBiotechNovo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech BioWorldShanghai Jeyou Pharmaceutical patents LGALS3 inhibitors BioWorldBoyuan Pharmaceutical prepares new HSV inhibitors BioWorldAntimicrobial compounds revealed in University of Hong Kong patent BioWorldYantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors BioWorldIn vivo mRNA gene therapy platform reprograms cytotoxic T cells LabiotechInside CSL’s strategy to simplify a biotech giant

Labiotech May 11, 2026

Inside CSL’s strategy to simplify a biotech giant

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. The post Inside CSL’s strategy to simplify a biotech gi...

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. The post Inside CSL’s strategy to simplify a biotech giant appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.